CY1106187T1 - Γονιδιο καταστολης - Google Patents

Γονιδιο καταστολης

Info

Publication number
CY1106187T1
CY1106187T1 CY20061101430T CY061101430T CY1106187T1 CY 1106187 T1 CY1106187 T1 CY 1106187T1 CY 20061101430 T CY20061101430 T CY 20061101430T CY 061101430 T CY061101430 T CY 061101430T CY 1106187 T1 CY1106187 T1 CY 1106187T1
Authority
CY
Cyprus
Prior art keywords
gene
modulating
tumor suppressor
encode polypeptides
polypeptides capable
Prior art date
Application number
CY20061101430T
Other languages
English (en)
Inventor
Xin Lu
Original Assignee
Ludwig Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019018A external-priority patent/GB0019018D0/en
Priority claimed from GB0029996A external-priority patent/GB0029996D0/en
Priority claimed from GB0112890A external-priority patent/GB0112890D0/en
Application filed by Ludwig Institute For Cancer Research filed Critical Ludwig Institute For Cancer Research
Publication of CY1106187T1 publication Critical patent/CY1106187T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Bipolar Transistors (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση σχετίζεται με την ταυτοποίηση ενός νέου μέλους της οικογένειας των γονιδίων καταστολής νεοπλασίας (πρωτεϊνών διέγερσης της απόπτωσης ASP's) που κωδικοποιούν πολυπεπτίδια ικανά να διαμορφώνουν τη δράση του γονιδίου p53 και κωδικοποιούν επίσης και πολυπεπτίδια ικανά να διαμορφώνουν τη δράση του εν λόγω πολυπεπτιδίου καταστολής νεοπλασίας.
CY20061101430T 2000-08-04 2006-10-04 Γονιδιο καταστολης CY1106187T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0019018A GB0019018D0 (en) 2000-08-04 2000-08-04 Suppressor gene
GB0029996A GB0029996D0 (en) 2000-12-08 2000-12-08 Suppressor gene
GB0112890A GB0112890D0 (en) 2001-05-26 2001-05-26 Suppressor Gene
PCT/GB2001/003524 WO2002012325A2 (en) 2000-08-04 2001-08-06 Suppressor gene

Publications (1)

Publication Number Publication Date
CY1106187T1 true CY1106187T1 (el) 2011-06-08

Family

ID=27255828

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101430T CY1106187T1 (el) 2000-08-04 2006-10-04 Γονιδιο καταστολης

Country Status (14)

Country Link
US (1) US20040053262A1 (el)
EP (2) EP1313762B1 (el)
JP (1) JP2004525605A (el)
CN (1) CN1310942C (el)
AT (1) ATE332309T1 (el)
AU (2) AU2001276515B2 (el)
CA (1) CA2417368A1 (el)
CY (1) CY1106187T1 (el)
DE (1) DE60121346T8 (el)
DK (1) DK1313762T3 (el)
ES (1) ES2269430T3 (el)
HK (1) HK1057377A1 (el)
PT (1) PT1313762E (el)
WO (1) WO2002012325A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852108B2 (en) 2002-05-14 2005-02-08 Spiration, Inc. Apparatus and method for resecting and removing selected body tissue from a site inside a patient
AU2003299132A1 (en) 2002-10-07 2004-04-23 Genome Research Limited P53 binding polypeptide
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
EP1697751A2 (en) * 2003-12-04 2006-09-06 Ludwig Institute For Cancer Research Assay and treatment
WO2005054862A1 (en) * 2003-12-04 2005-06-16 Ludwig Institute For Cancer Research Screening assay and treatment
GB0328690D0 (en) 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
WO2005093098A1 (en) * 2004-03-12 2005-10-06 Ludwig Institute For Cancer Research Differential drug sensitivity
CA3204588A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
PL1838350T3 (pl) 2005-01-20 2015-02-27 Ryboquin Company Ltd Modulatory aktywności ubikwitynazy itch
WO2008045344A2 (en) * 2006-10-06 2008-04-17 The General Hospital Corporation Methods to determine responsiveness to cisplatin treatment
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
WO2010062960A2 (en) * 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
CN102625711A (zh) * 2009-09-10 2012-08-01 梅约医学教育与研究基金会 调节去泛素化酶和泛素化多肽的方法和材料
WO2013131019A1 (en) 2012-03-02 2013-09-06 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential
CN105246501B (zh) 2013-03-27 2021-01-12 雪松-西奈医学中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN106874709B (zh) * 2015-12-12 2019-03-01 北京大学 测序结果中序列数据错误的检测和校正方法
CN116083547A (zh) 2015-11-19 2023-05-09 赛纳生物科技(北京)有限公司 一种校正测序期间超前量的方法
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
WO2000020587A2 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7141384B1 (en) * 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
WO2000032628A1 (fr) * 1998-12-03 2000-06-08 Ono Pharmaceutical Co., Ltd. INHIBITEUR DE LIAISON DE Re1A, PROCEDE DE PRODUCTION CORRESPONDANT ET UTILISATION DUDIT INHIBITEUR DE LIAISON
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20040053262A1 (en) 2004-03-18
ES2269430T3 (es) 2007-04-01
ATE332309T1 (de) 2006-07-15
EP1710582A2 (en) 2006-10-11
AU7651501A (en) 2002-02-18
DE60121346D1 (en) 2006-08-17
WO2002012325A3 (en) 2003-03-06
AU2001276515B2 (en) 2006-10-12
DK1313762T3 (da) 2006-10-30
PT1313762E (pt) 2006-11-30
JP2004525605A (ja) 2004-08-26
WO2002012325A2 (en) 2002-02-14
CN1310942C (zh) 2007-04-18
CN1446228A (zh) 2003-10-01
CA2417368A1 (en) 2002-02-14
EP1313762A2 (en) 2003-05-28
HK1057377A1 (en) 2004-04-02
EP1313762B1 (en) 2006-07-05
EP1710582A3 (en) 2006-11-02
DE60121346T2 (de) 2007-07-19
DE60121346T8 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
CY1106187T1 (el) Γονιδιο καταστολης
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
DK0670899T3 (da) Varmeshockproteiner og behandling af tumorer
BR0316435A (pt) Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos
ATE371727T1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
DE69900746D1 (de) Gesteuerte verabreichung von peptiden oder proteinen
DE69421624T2 (de) Medikamente bindendes protein
CY1106323T1 (el) Διαγονιδιακα φυτα ανθεκτικα σε εντομα και μεθοδοι για βελτιωση δραστικοτητας δελτα-ενδοτοξινης εναντι εντομων στοχων
EA200000311A1 (ru) Новый белок иммунной системы - кау
DE60041505D1 (de) Inzektizide proteinen von bacillus thuringiensis
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
DE69826079D1 (de) Lokalisator von elektrisch leitenden objekten
PT839194E (pt) Variantesda proteina p53 e utilizacoes terapeuticas.
NO971059D0 (no) Modifiserte human-C3-proteiner
ATE439441T1 (de) Veränderte, fluoreszierende proteine
BR9710919A (pt) Proteina purificada sr-p70
DE69831231D1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
YU21292A (sh) Insekticidno efektivni peptidi
DE60133273D1 (de) Inhibitoren von peptid deformylase
DE3880226T2 (de) Derivate von calcitonin verwandten gen-peptiden.
FR2697850B1 (fr) Nouveaux polypeptides ayant une activité de récepteur opioïde, acides nucléiques codant pour ces polypeptides et utilisations.
PT1140994E (pt) Proteinas da superficie externa, suas genes e sua utilizacao
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes